ABSTRACT
The COVID-19 pandemic caused by SARS-CoV-2 requires new treatments both to alleviate the symptoms and to prevent the spread of this disease. Previous studies demonstrated good antiviral and virucidal activity of phospholipase A2s (PLA2s) from snake venoms against viruses from different families but there was no data for coronaviruses. Here we show that PLA2s from snake venoms protect Vero E6 cells against SARS-CoV-2 cytopathic effects. PLA2s showed low cytotoxicity to Vero E6 cells with some activity at micromolar concentrations, but strong antiviral activity at nanomolar concentrations. Dimeric PLA2 from the viper Vipera nikolskii and its subunits manifested especially potent virucidal effects, which were related to their phospholipolytic activity, and inhibited cell-cell fusion mediated by the SARS-CoV-2 spike glycoprotein. Moreover, PLA2s interfered with binding both of an antibody against ACE2 and of the receptor-binding domain of the glycoprotein S to 293T/ACE2 cells. This is the first demonstration of a detrimental effect of PLA2s on ß-coronaviruses. Thus, snake PLA2s are promising for the development of antiviral drugs that target the viral envelope, and could also prove to be useful tools to study the interaction of viruses with host cells.
Subject(s)
Phospholipases A2/pharmacology , SARS-CoV-2/drug effects , Spike Glycoprotein, Coronavirus/metabolism , Viper Venoms/pharmacology , Virus Attachment/drug effects , Angiotensin-Converting Enzyme 2/metabolism , Animals , Antibody Affinity/drug effects , Antiviral Agents/pharmacology , Cell Fusion , Cell Line , Chlorocebus aethiops , Cytopathogenic Effect, Viral/drug effects , HEK293 Cells , Humans , Models, Molecular , Protein Domains/drug effects , Surface Plasmon Resonance , Vero Cells , Viper Venoms/enzymology , COVID-19 Drug TreatmentABSTRACT
Pathogenesis in seropositive neuromyelitis optica spectrum disorders (herein called NMO) involves binding of IgG1 autoantibodies to aquaporin-4 (AQP4) on astrocytes in the central nervous system, which initiates complement and cellular injury. We previously developed an antibody blocking approach for potential therapy of NMO in which an engineered, monoclonal, anti-AQP4 antibody lacking cytotoxicity effector functions (called aquaporumab) blocked binding of NMO autoantibodies to astrocyte AQP4 (Tradtrantip et al. Ann. Neurol. 71, 314-322, 2012). Here, a high-affinity aquaporumab, which was generated by affinity maturation using saturation mutagenesis, was shown to block cellular injury caused by NMO patient sera. Anti-AQP4 antibody rAb-53, a fully human antibody with effector function neutralizing Fc mutations L234A/L235A and affinity-enhancing Fab mutations Y50R/S56R, called AQmabAM, bound to AQP4 in cell cultures with Kd ~ 18 ng/ml (~0.12 nM), ~8-fold greater affinity than the original antibody. AQmabAM, but without L234A/L235A Fc mutations, produced complement-dependent cytotoxicity (CDC) with EC50 ~ 82 ng/ml. AQmabAM prevented CDC produced by sera from eight NMO patients with IC50 ranging from 40 to 80 ng/ml, and similarly prevented antibody-dependent cellular cytotoxicity (ADCC). Mechanistic studies demonstrated that AQmabAM blocked binding of serum NMO autoantibodies to AQP4. AQmabAM offers a targeted, non-immunosuppressive approach for therapy of seropositive NMO. Autoantibody blocking may be a useful therapeutic strategy for other autoimmune diseases as well.
Subject(s)
Antibodies, Blocking/pharmacology , Antibody Affinity/drug effects , Antibody-Dependent Cell Cytotoxicity/drug effects , Aquaporin 4/immunology , Autoantibodies/immunology , Immunoglobulin G/pharmacology , Neuromyelitis Optica/drug therapy , Recombinant Proteins/pharmacology , Animals , Antibodies, Blocking/therapeutic use , Antibodies, Monoclonal , Antibody Affinity/genetics , Antibody-Dependent Cell Cytotoxicity/genetics , Binding, Competitive , CHO Cells , Cell Survival/drug effects , Complement System Proteins/immunology , Cricetulus , Cytotoxicity Tests, Immunologic , Humans , Immunoglobulin G/genetics , Killer Cells, Natural , Mutagenesis , Neuromyelitis Optica/immunology , SerumABSTRACT
Therapeutic antibodies are the fastest growing class of drugs in the treatment of cancer, and autoimmune and inflammatory diseases that require the concomitant development of assays to monitor therapeutic antibody levels. Here, we demonstrate that the use of Affimer nonantibody binding proteins provides an advantage over current antibody-based detection systems. For four therapeutic antibodies, we used phage display to isolate highly specific anti-idiotypic Affimer reagents, which selectively bind to the therapeutic antibody idiotype. For each antibody target the calibration curves met US Food and Drug Administration criteria and the dynamic range compared favorably with commercially available reagents. Affimer proteins therefore represent promising anti-idiotypic reagents that are simple to select and manufacture, and that offer the sensitivity, specificity and consistency required for pharmacokinetic assays.
Subject(s)
Antibodies, Monoclonal/pharmacokinetics , Antibody Affinity/drug effects , Biological Therapy/methods , Animals , HumansABSTRACT
BACKGROUND: Herpes simplex virus type 1 (HSV1), establishes life-long latency and can cause symptoms during both first-time infection and later reactivation. The aim of the present study was to describe a protocol to generate a reliable and discriminative avidity index (AI) for anti-HSV1 IgG content in human sera. METHODS: Human serum from two distinct cohorts; one a biobank collection (Betula) (n = 28), and one from a clinical diagnostics laboratory at Northern Sweden University Hospital (NUS) (n = 18), were assessed for presence of IgG antibodies against HSV1 by a commercially available ELISA-kit. Addition of urea at the incubation step reduces effective binding, and the ratio between urea treated sample and non-treated sample was used to express an avidity index (AI) for individual samples. RESULTS: AI score ranged between 43.2 and 73.4% among anti-HSV1 positive biobank sera. Clinical samples ranged between 36.3 and 74.9%. Reproducibility expressed as an intraclass correlation coefficient (ICC) was estimated at 0.948 (95% CI: 0.900-0.979) and 0.989 (95% CI 0.969-0.996) in the biobank and clinical samples, respectively. CONCLUSION: The method allows for AI scoring of anti-HSV1 IgG from individual human sera with a single measurement. The least significant change between two measurements at the p < 0.05 level was estimated at 5.4 and 3.2 points, respectively, for the two assessed cohorts.
Subject(s)
Antibodies, Viral/analysis , Antibody Affinity/drug effects , Herpesvirus 1, Human/immunology , Immunoglobulin G/analysis , Serologic Tests/methods , Urea/pharmacology , Adult , Aged , Aged, 80 and over , Antibodies, Viral/blood , Antibodies, Viral/drug effects , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Immunoglobulin G/metabolism , Immunoglobulin M/blood , Indicator Dilution Techniques , Male , Middle Aged , Reagent Kits, Diagnostic , Reproducibility of ResultsABSTRACT
Aggregation of tau protein and spreading of tau aggregates are pivotal pathological processes in a range of neurological disorders. Accumulating evidence suggests that immunotherapy targeting tau may be a viable therapeutic strategy. We have previously described the isolation of antibody CBTAU-22.1 from the memory B-cell repertoire of healthy human donors. CBTAU-22.1 was shown to specifically bind a disease-associated phosphorylated epitope in the C-terminus of tau (Ser422) and to be able to inhibit the spreading of pathological tau aggregates from P301S spinal cord lysates in vitro, albeit with limited potency. Using a combination of rational design and random mutagenesis we have derived a variant antibody with improved affinity while maintaining the specificity of the parental antibody. This affinity improved antibody showed greatly enhanced potency in a cell-based immunodepletion assay using paired helical filaments (PHFs) derived from human Alzheimer's disease (AD) brain tissue. Moreover, the affinity improved antibody limits the in vitro aggregation propensity of full length tau species specifically phosphorylated at position 422 produced by employing a native chemical ligation approach. Together, these results indicate that in addition to being able to inhibit the spreading of pathological tau aggregates, the matured antibody can potentially also interfere with the nucleation of tau which is believed to be the first step of the pathogenic process. Finally, the functionality in a P301L transgenic mice co-injection model highlights the therapeutic potential of human antibody dmCBTAU-22.1.
Subject(s)
Alzheimer Disease/drug therapy , Alzheimer Disease/pathology , Antibodies/pharmacology , Brain/metabolism , Serine/metabolism , tau Proteins/immunology , tau Proteins/metabolism , Aged , Aged, 80 and over , Alzheimer Disease/metabolism , Animals , Antibody Affinity/drug effects , Autopsy , Brain/pathology , Dose-Response Relationship, Drug , Epitopes/metabolism , Female , Humans , Male , Mice , Mice, Transgenic , Microscopy, Atomic Force , Middle Aged , Models, Molecular , Mutagenesis , Mutation/genetics , Phosphorylation/physiology , Protein Aggregation, Pathological/metabolism , Protein Aggregation, Pathological/pathology , Protein Aggregation, Pathological/therapyABSTRACT
Xanthine oxidase (XOD) is a key enzyme that catalyzes xanthine to uric acid. Most of the urate-lowering medicines targeting XOD have a limited effect on alleviating inflammation in spite of significant effects on decreasing serum uric acid level. In this study, we produced and characterized a novel monoclonal antibody (Anti-XOD mAb) using hybridoma technology based on a novel peptide OI5P-1(O-IA2(5)-P2-1),which containing a B-cell epitope of XOD and a novel Th2 built-in adjuvant I5P-1(IA2(5)-P2-1). Results of western blotting and cross-reactivity assay indicated that the mAb binds specifically to XOD and the affinity was 2.523×1010L/mol. The mAb reduced serum uric acid level and hepatic xanthine oxidase activity in potassium oxonate induced mice. A decreased methane dicarboxylic aldehyde level and an improved superoxide dismutase level in mAb treated mice indicated anti-lipid peroxidation effects of the mAb. Moreover, the mAb showed a significant immunomodulatory effect which could shift Th1/Th2 balance to Th2-dominant immunity. The mAb treatment alleviates inflammation induced by potassium oxonate, superior to the small molecule allopurinol treatment. For the first time, these results showed that the anti-XOD mAb may serve as a promising therapeutic approach for inflammatory response related to uric acid.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Immunoglobulin G/therapeutic use , Inflammation/drug therapy , Xanthine Oxidase/antagonists & inhibitors , Allopurinol/pharmacology , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/isolation & purification , Antibodies, Monoclonal/pharmacology , Antibody Affinity/drug effects , Antioxidants/metabolism , Creatinine/blood , Cross Reactions/immunology , Female , Immune Sera , Immunization , Immunoglobulin G/pharmacology , Inflammation/blood , Inflammation/pathology , Kidney/drug effects , Liver/enzymology , Malondialdehyde/blood , Mice , Mice, Inbred BALB C , Oxonic Acid , Protective Agents/pharmacology , Spleen/pathology , Superoxide Dismutase/blood , Th1 Cells/drug effects , Th1 Cells/immunology , Th2 Cells/drug effects , Th2 Cells/immunology , Urea/blood , Uric Acid/blood , Xanthine Oxidase/metabolismABSTRACT
Adoptive transfer of high-affinity chimeric antigen receptor (CAR) T cells targeting hematological cancers has yielded impressive clinical results. However, safety concerns regarding target expression on healthy tissue and poor efficacy have hampered application to solid tumors. Here, a panel of affinity-variant CARs were constructed targeting overexpressed ICAM-1, a broad tumor biomarker, using its physiological ligand, LFA-1. Anti-tumor T cell potency in vitro was directly proportional to CAR affinity and ICAM-1 density. In a solid tumor mouse model allowing simultaneous monitoring of anti-tumor potency and systemic off-tumor toxicity, micromolar affinity CAR T cells demonstrated superior anti-tumor efficacy and safety compared to their nanomolar counterparts. Longitudinal T cell tracking by PET/CT and concurrent cytokine measurement revealed superior expansion and contraction kinetics of micromolar affinity CAR T cells. Therefore, we developed an ICAM-1 specific CAR with broad anti-tumor applicability that utilized a reduced affinity targeting strategy to significantly boost efficacy and safety.
Subject(s)
Immunotherapy, Adoptive/methods , Intercellular Adhesion Molecule-1/drug effects , Intercellular Adhesion Molecule-1/immunology , Animals , Antibody Affinity/drug effects , Cell Line , Cell Line, Tumor , Hematologic Neoplasms/metabolism , Humans , Lentivirus/metabolism , Ligands , Mice , Mice, Nude , Positron Emission Tomography Computed Tomography , Receptors, Antigen, T-Cell/metabolism , Receptors, Chimeric Antigen/metabolism , T-Lymphocytes/immunology , Xenograft Model Antitumor AssaysABSTRACT
AIMS: To optimise the ELISA method for the avidity of IgG antibodies against neurofilament heavy chain (NfH) and to determine the levels and avidity of anti-NfH antibodies in patients with Alzheimer's disease (AD) and a healthy control group. METHODS: Various dilutions of sera and concentrations of urea and sodium chloride as chaotropic reagents were tested in the process of the ELISA optimisation. The levels and avidity of anti-NfH antibodies were determined in 30 patients with Alzheimer's disease and 30 age-matched cognitively normal elderly adults. RESULTS: Sera dilution 1:200 and urea as a chaotrope in a concentration 6 mol/L were chosen to be the most suitable for the avidity assay of anti-NfH antibodies by ELISA. The results showed no differences in either level or avidity of IgG anti-NfH antibodies between AD patients and cognitively normal persons. The levels of anti-NfH IgG antibodies inversely correlated with their avidities. CONCLUSIONS: We optimised the ELISA method for the determination of anti-NfH antibody avidity determination which is suitable for research of anti-NfH antibody avidity in patients with neurological diseases associated with neurocytoskeletal defects. The determination of serum anti-NfH antibody avidity in AD patients seems to have limited diagnostic significance.
Subject(s)
Alzheimer Disease/blood , Alzheimer Disease/immunology , Antibodies/blood , Antibody Affinity/drug effects , Immunoglobulin G/blood , Intermediate Filaments/drug effects , Aged , Enzyme-Linked Immunosorbent Assay , Female , Humans , MaleSubject(s)
Antibody Affinity/drug effects , Biotin/therapeutic use , Hyperthyroidism/diagnosis , Thyroid Function Tests , Thyroid Gland/immunology , Aged , Biotin/pharmacology , False Positive Reactions , Humans , Immunoassay , Male , Multiple Sclerosis/drug therapy , Thyroid Gland/diagnostic imaging , Thyroid Gland/physiopathology , Thyroxine/metabolism , Triiodothyronine/metabolismABSTRACT
In relation to the recent trials of Intravenous Immunoglobulin (IVIG) in Alzheimer's Disease (AD) it was demonstrated that different IgG preparations contain varying amounts of natural anti-amyloid ß (Aß) antibodies as measured by ELISA. We therefore investigated the relevance of ELISA data for measuring low-affinity antibodies, such as anti-Aß. We analysed the binding of different commercial Immunoglobulin G (IgG) preparations to Aß, actin and tetanus toxoid in different binding assays to further investigate the possible cause for observed differences in binding to Aß and actin between different IgG preparations. We show that the differences of commercial IgG preparations in binding to Aß and actin in ELISA assays are artefactual and only evident in in vitro binding assays. In functional assays and in vivo animal studies the different IVIG preparations exhibited very similar potency. ELISA data alone are not appropriate to analyse and rank the binding capacity of low-affinity antibodies to Aß or other endogenous self-antigens contained in IgG preparations. Additional analytical methods should be adopted to complement ELISA data.
Subject(s)
Antigens/immunology , Autoantigens/immunology , Immunoglobulin G/immunology , Immunoglobulins, Intravenous/immunology , Actins/immunology , Actins/metabolism , Alzheimer Disease/drug therapy , Alzheimer Disease/immunology , Alzheimer Disease/metabolism , Amyloid beta-Peptides/immunology , Amyloid beta-Peptides/metabolism , Animals , Antibody Affinity/drug effects , Antibody Affinity/immunology , Antigens/metabolism , Autoantigens/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Herpesvirus 3, Human/immunology , Herpesvirus 3, Human/metabolism , Humans , Immunoglobulin G/metabolism , Immunoglobulins, Intravenous/pharmacology , Peptide Fragments/immunology , Peptide Fragments/metabolism , Protein Binding/drug effects , Protein Binding/immunology , Rats , Tetanus Toxoid/immunology , Tetanus Toxoid/metabolismABSTRACT
INTRODUCTION: Neuromyelitis optica (NMO), an autoimmune astrocytopathic disease associated with anti-aquaporin-4 (AQP4) antibody, is characterized by extensive necrotic lesions preferentially involving the optic nerves and spinal cord. However, previous in-vivo experimental models injecting human anti-AQP4 antibodies only resulted in mild spinal cord lesions compared to NMO autopsied cases. Here, we investigated whether the formation of severe NMO-like lesions occurs in Lewis rats in the context of experimental autoimmune encephalomyelitis (EAE), intraperitoneally injecting incremental doses of purified human immunoglobulin-G from a NMO patient (hIgGNMO) or a high affinity anti-AQP4 monoclonal antibody (E5415A), recognizing extracellular domain of AQP4 made by baculovirus display method. RESULTS: NMO-like lesions were observed in the spinal cord, brainstem, and optic chiasm of EAE-rats with injection of pathogenic IgG (hIgGNMO and E5415A), but not in control EAE. Only in higher dose E5415A rats, there were acute and significantly severer clinical exacerbations (tetraparesis or moribund) compared with controls, within half day after the injection of pathogenic IgG. Loss of AQP4 was observed both in EAE rats receiving hIgGNMO and E5415A in a dose dependent manner, but the ratio of AQP4 loss in spinal sections became significantly larger in those receiving high dose E5415A up to about 50 % than those receiving low-dose E5415A or hIgGNMO less than 3 %. These lesions were also characterized by extensive loss of glial fibrillary acidic protein but relatively preserved myelin sheaths with perivascular deposition of IgG and C5b-9, which is compatible with post mortem NMO pathology. In high dose E5415A rats, massive neutrophil infiltration was observed especially at the lesion edge, and such lesions were highly vacuolated with partial demyelination and axonal damage. In contrast, such changes were absent in EAE rats receiving low-dose E5415A and hIgGNMO. CONCLUSIONS: In the present study, we established a severe experimental NMO rat model with highly clinical exacerbation and extensive tissue destructive lesions typically observed in NMO patients, which has not adequately been realized in in-vivo rodent models. Our data suggest that the pathogenic antibodies could induce immune mediated astrocytopathy with mobilized neutrophils, resulted in early lesion expansion of NMO lesion with vacuolation and other tissue damages. (350/350).
Subject(s)
Aquaporin 4/immunology , Astrocytes/pathology , Immunoglobulin G/adverse effects , Neuromyelitis Optica/chemically induced , Neuromyelitis Optica/pathology , Aged , Animals , Antibody Affinity/drug effects , Astrocytes/metabolism , Calcium-Binding Proteins/metabolism , Complement C9/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Humans , Microfilament Proteins/metabolism , Nerve Tissue Proteins/metabolism , Neutrophil Infiltration/drug effects , Neutrophil Infiltration/physiology , Rats , Rats, Inbred Lew , Time Factors , Vacuoles/pathologyABSTRACT
UNLABELLED: There is a major need for new adjuvants to improve the efficacy of seasonal and pandemic influenza vaccines. Advax is a novel polysaccharide adjuvant based on delta inulin that has been shown to enhance the immunogenicity of influenza vaccine in animal models and human clinical trials. To better understand the mechanism for this enhancement, we sought to assess its effect on the plasmablast response in human subjects. This pilot study utilised cryopreserved 7 day post-vaccination (7dpv) peripheral blood mononuclear cell samples obtained from a subset of 25 adult subjects from the FLU006-12 trial who had been immunized intramuscularly with a standard dose of 2012 trivalent inactivated influenza vaccine (TIV) alone (n=9 subjects) or combined with 5mg (n=8) or 10mg (n=8) of Advax adjuvant. Subjects receiving Advax adjuvant had increased 7dpv plasmablasts, which in turn exhibited a 2-3 fold higher rate of non-silent mutations in the B-cell receptor CDR3 region associated with higher expression of activation-induced cytidine deaminase (AID), the major enzyme controlling BCR affinity maturation. Together, these data suggest that Advax adjuvant enhances influenza immunity in immunized subjects via multiple mechanisms including increased plasmablast generation, AID expression and CDR3 mutagenesis resulting in enhanced BCR affinity maturation and increased production of high avidity antibody. How Advax adjuvant achieves these beneficial effects on plasmablasts remains the subject of ongoing investigation. TRIAL REGISTRATION: Australia New Zealand Clinical Trials Register ACTRN12612000709842 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=362709.
Subject(s)
Antibody Affinity/immunology , Cytidine Deaminase/metabolism , Influenza Vaccines/immunology , Inulin/analogs & derivatives , Plasma Cells/immunology , Seasons , Adult , Aged , Aged, 80 and over , Antibody Affinity/drug effects , Antibody Formation/drug effects , Complementarity Determining Regions/genetics , Complementarity Determining Regions/immunology , Female , Humans , Immunoglobulin G/immunology , Influenza Vaccines/administration & dosage , Influenza Vaccines/pharmacology , Inulin/administration & dosage , Inulin/pharmacology , Male , Middle Aged , Mutation/genetics , Plasma Cells/drug effects , Receptors, Antigen, B-Cell/metabolism , Vaccination , Young AdultABSTRACT
Interactions between dendritic cells (DCs) and T cells control the decision between activation and tolerance induction. Thromboxane A2 (TXA2) and its receptor TP have been suggested to regulate adaptive immune responses through control of T cell-DC interactions. Here, we show that this control is achieved by selectively reducing expansion of low-avidity CD4(+) T cells. During inflammation, weak tetramer-binding TP-deficient CD4(+) T cells were preferentially expanded compared with TP-proficient CD4(+) T cells. Using intravital imaging of cellular interactions in reactive peripheral lymph nodes (PLNs), we found that TXA2 led to disruption of low- but not high-avidity interactions between DCs and CD4(+) T cells. Lack of TP correlated with higher expression of activation markers on stimulated CD4(+) T cells and with augmented accumulation of follicular helper T cells (TFH), which correlated with increased low-avidity IgG responses. In sum, our data suggest that tonic suppression of weak CD4(+) T cell-DC interactions by TXA2-TP signaling improves the overall quality of adaptive immune responses.
Subject(s)
Antibody Affinity/drug effects , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Cell Communication/drug effects , Dendritic Cells/cytology , Immunologic Factors/pharmacology , Thromboxane A2/pharmacology , Animals , Biomarkers/metabolism , CD4-Positive T-Lymphocytes/drug effects , Chickens , Dendritic Cells/drug effects , Dendritic Cells/immunology , Histocompatibility Antigens/immunology , Immunoglobulin G/biosynthesis , Inflammation/pathology , Lymphocyte Activation/drug effects , Lymphocyte Count , Male , Mice, Inbred C57BL , Mice, Transgenic , Microscopy, Fluorescence, Multiphoton , Ovalbumin/immunology , Receptors, Thromboxane A2, Prostaglandin H2/deficiency , Receptors, Thromboxane A2, Prostaglandin H2/metabolism , Signal Transduction/drug effects , T-Lymphocytes, Helper-Inducer/drug effects , T-Lymphocytes, Helper-Inducer/immunologyABSTRACT
Recent studies have demonstrated important roles of nucleic acid-sensing Toll-like receptors (TLRs) in promoting protective antibody responses against several viruses. To dissect how recognition of nucleic acids by TLRs enhances germinal center (GC) responses, mice selectively deleted for myeloid differentiation primary-response protein 88 (MyD88) in B cells or dendritic cells (DCs) were immunized with a haptenated protein antigen bound to a TLR9 ligand. TLR9 signaling in DCs led to greater numbers of follicular helper T (TFH) cells and GC B cells, and accelerated production of broad-affinity antihapten IgG. In addition to modulating GC selection by increasing inducible costimulator (ICOS) expression on TFH cells and reducing the number of follicular regulatory T cells, MyD88-dependent signaling in B cells enhanced GC output by augmenting a class switch to IgG2a, affinity maturation, and the memory antibody response. Thus, attachment of a TLR9 ligand to an oligovalent antigen acted on DCs and B cells to coordinate changes in the T-cell compartment and also promoted B cell-intrinsic effects that ultimately programmed a more potent GC response.
Subject(s)
Antibody Formation/immunology , Germinal Center/immunology , Signal Transduction/immunology , Toll-Like Receptor 9/metabolism , Animals , Antibody Affinity/drug effects , Antibody Formation/drug effects , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Chickens , Dendritic Cells/drug effects , Dendritic Cells/immunology , Forkhead Transcription Factors/metabolism , Haptens/pharmacology , Immunologic Memory/drug effects , Ligands , Lymphocyte Activation/drug effects , Lymphocyte Count , Mice , Mice, Inbred C57BL , Myeloid Differentiation Factor 88/metabolism , Nitrophenols/pharmacology , Phenotype , gamma-Globulins/pharmacologyABSTRACT
Immune regulating functions of lipid mediators are being recognized. Prostaglandins (PGs) are derived from phospholipid by cyclooxygenase-2 (COX-2) in inflammatory tissues. Based upon our previous data that imply an immune modulating activity of prostacyclin, we hypothesized that PGs promote the humoral immune responses in vivo. To test this hypothesis, we examined the effect of a prostacyclin analog beraprost and PGE2 on the antibody responses that were induced by immunizing mice with keyhole limpet hemocyanin (KLH). Beraprost was used due to the extremely unstable property of prostacyclin. Our results showed that beraprost indeed promoted the production of anti-KLH antibodies, which was dose-dependent and specific to beraprost because PGE2 did not modulate the antibody response compared with controls. The enhancing effect of beraprost was reproduced in the secondary responses, suggesting that memory B cell generation during the primary response was significantly affected by beraprost. Analysis of the isotypes of anti-KLH antibodies revealed that beraprost stimulated the production of IgA and IgG subisotypes but not IgM. However, germinal center B cell generation and the affinity of anti-KLH antibodies were not affected by beraprost administration. To confirm these results we immunized COX-2 knockout mice with KLH and analyzed whether the results with wild-type mice were reflected in the absence of PGs. The primary and secondary antibody responses were significantly impaired in the KO animals. The levels of anti-KLH IgG subisotypes and IgA were severely reduced in KO mice whereas those of IgM were comparable to controls. These results reveal an unrecognized function of PG in the humoral immune responses.
Subject(s)
Antibody Affinity/drug effects , B-Lymphocytes/drug effects , Epoprostenol/analogs & derivatives , Germinal Center/drug effects , Immunity, Humoral/drug effects , Immunoglobulin G/immunology , Animals , Antibody Affinity/immunology , Antigens/immunology , B-Lymphocytes/immunology , Cyclooxygenase 2/genetics , Dinoprostone/biosynthesis , Dinoprostone/immunology , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Epoprostenol/pharmacology , Flow Cytometry , Germinal Center/immunology , Hemocyanins/immunology , Immunity, Humoral/immunology , Immunoglobulin A/biosynthesis , Immunoglobulin A/blood , Immunoglobulin A/immunology , Immunoglobulin G/blood , Immunoglobulin M/biosynthesis , Immunoglobulin M/blood , Immunoglobulin M/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein IsoformsABSTRACT
BACKGROUND AND PURPOSE: Blood-stage Plasmodium parasites cause morbidity and mortality from malaria. Parasite resistance to drugs makes development of new chemotherapies an urgency. Aminoacyl-tRNA synthetases have been validated as antimalarial drug targets. We explored long-term effects of borrelidin and mupirocin in lethal P. yoelii murine malaria. EXPERIMENTAL APPROACH: Long-term (up to 340 days) immunological responses to borrelidin or mupirocin were measured after an initial 4 day suppressive test. Prophylaxis and cure were evaluated and the inhibitory effect on the parasites analysed. KEY RESULTS: Borrelidin protected against lethal malaria at 0.25 mg·kg⻹·day⻹. Antimalarial activity of borrelidin correlated with accumulation of trophozoites in peripheral blood. All infected mice treated with borrelidin survived and subsequently developed immunity protecting them from re-infection on further challenges, 75 and 340 days after the initial infection. This long-term immunity in borrelidin-treated mice resulted in negligible parasitaemia after re-infections and marked increases in total serum levels of antiparasite IgGs with augmented avidity. Long-term memory IgGs mainly reacted against high and low molecular weight parasite antigens. Immunofluorescence microscopy showed that circulating IgGs bound predominantly to late intracellular stage parasites, mainly schizonts. CONCLUSIONS AND IMPLICATIONS: Low borrelidin doses protected mice from lethal malaria infections and induced protective immune responses after treatment. Development of combination therapies with borrelidin and selective modifications of the borrelidin molecule to specifically inhibit plasmodial threonyl tRNA synthetase should improve therapeutic strategies for malaria.
Subject(s)
Antimalarials/therapeutic use , Immunity, Humoral/drug effects , Malaria/drug therapy , Parasitemia/drug therapy , Plasmodium yoelii/drug effects , Threonine-tRNA Ligase/antagonists & inhibitors , Animals , Antibodies, Protozoan/analysis , Antibodies, Protozoan/metabolism , Antibody Affinity/drug effects , Antimalarials/pharmacology , Drug Evaluation, Preclinical , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Fatty Alcohols/pharmacology , Fatty Alcohols/therapeutic use , Female , Malaria/immunology , Malaria/parasitology , Malaria/prevention & control , Mice , Mice, Inbred Strains , Mupirocin/therapeutic use , Parasitemia/immunology , Parasitemia/parasitology , Parasitemia/prevention & control , Plasmodium yoelii/immunology , Plasmodium yoelii/isolation & purification , Plasmodium yoelii/physiology , Protozoan Proteins/blood , Protozoan Proteins/isolation & purification , Protozoan Proteins/metabolism , Random Allocation , Schizonts/drug effects , Schizonts/immunology , Schizonts/metabolism , Schizonts/physiology , Secondary Prevention , Specific Pathogen-Free Organisms , Survival AnalysisABSTRACT
INTRODUCTION: The Post-exposure Prophylaxis in Infants (PEPI)-Malawi trial evaluated infant antiretroviral regimens for prevention of post-natal HIV transmission. A multi-assay algorithm (MAA) that includes the BED capture immunoassay, an avidity assay, CD4 cell count, and viral load was used to identify women who were vs. were not recently infected at the time of enrollment (MAA recent, Nâ=â73; MAA non-recent, Nâ=â2,488); a subset of the women in the MAA non-recent group known to have been HIV infected for at least 2 years before enrollment (known non-recent, Nâ=â54). Antibody maturation and viral diversification were examined in these women. METHODS: Samples collected at enrollment (Nâ=â2,561) and 12-24 months later (Nâ=â1,306) were available for serologic analysis using the BED and avidity assays. A subset of those samples was used for analysis of viral diversity, which was performed using a high resolution melting (HRM) diversity assay. Viral diversity analysis was performed using all available samples from women in the MAA recent group (61 enrollment samples, 38 follow-up samples) and the known non-recent group (43 enrollment samples, 22 follow-up samples). Diversity data from PEPI-Malawi were also compared to similar data from 169 adults in the United States (US) with known recent infection (Nâ=â102) and known non-recent infection (Nâ=â67). RESULTS: In PEPI-Malawi, results from the BED and avidity assays increased over time in the MAA recent group, but did not change significantly in the MAA non-recent group. At enrollment, HIV diversity was lower in the MAA recent group than in the known non-recent group. HRM diversity assay results from women in PEPI-Malawi were similar to those from adults in the US with known duration of HIV infection. CONCLUSIONS: Antibody maturation and HIV diversification patterns in African women provide additional support for use of the MAA to identify populations with recent HIV infection.
Subject(s)
Genetic Variation , HIV Antibodies/immunology , HIV Infections/immunology , HIV Infections/virology , HIV-1/genetics , HIV-1/immunology , Adult , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Antibody Affinity/drug effects , Antibody Affinity/immunology , Female , Follow-Up Studies , Genetic Variation/drug effects , HIV Infections/blood , HIV Infections/drug therapy , HIV-1/drug effects , Humans , Immunoassay , Malawi , Nucleic Acid Denaturation/drug effects , Post-Exposure Prophylaxis , United StatesABSTRACT
BACKGROUND: Viral suppression and viral breakthrough impact the humoral immune response to HIV infection. We evaluated the impact of viral suppression and viral breakthrough on results obtained with two cross-sectional HIV incidence assays. METHODS: All samples were collected from adults in the US who were HIV infected for >2 years. Samples were tested with the BED capture enzyme immunoassay (BED-CEIA) which measures the proportion of IgG that is HIV-specific, and with an antibody avidity assay based on the Genetic Systems 1/2+ O ELISA. We tested 281 samples: (1) 30 samples from 18 patients with natural control of HIV-1 infection known as elite controllers or suppressors (2) 72 samples from 18 adults on antiretroviral therapy (ART), with 1 sample before and 2-6 samples after ART initiation, and (3) 179 samples from 20 virally-suppressed adults who had evidence of viral breakthrough receiving ART (>400 copies/ml HIV RNA) and with subsequent viral suppression. RESULTS: For elite suppressors, 10/18 had BED-CEIA values <0.8 normalized optical density units (OD-n) and these values did not change significantly over time. For patients receiving ART, 14/18 had BED-CEIA values that decreased over time, with a median decrease of 0.42 OD-n (range 0.10 to 0.63)/time point receiving ART. Three patterns of BED-CEIA values were observed during viral breakthrough: (1) values that increased then returned to pre-breakthrough values when viral suppression was re-established, (2) values that increased after viral breakthrough, and (3) values that did not change with viral breakthrough. CONCLUSIONS: Viral suppression and viral breakthrough were associated with changes in BED-CEIA values, reflecting changes in the proportion of HIV-specific IgG. These changes can result in misclassification of patients with long-term HIV infection as recently infected using the BED-CEIA, thereby influencing a falsely high value for cross-sectional incidence estimates.
Subject(s)
Anti-HIV Agents/therapeutic use , Antibody Affinity/immunology , HIV Antibodies/immunology , HIV Infections/immunology , HIV Infections/virology , HIV-1/immunology , Anti-HIV Agents/pharmacology , Antibody Affinity/drug effects , HIV Infections/classification , HIV Infections/drug therapy , HIV-1/drug effects , Humans , Immunoenzyme Techniques , Time FactorsABSTRACT
Folate supplementation reduces the risk of neural tube defect (NTD) pregnancy, and folinic acid has been used to correct cerebral folate deficiency (CFD) in children with developmental disorders. In the absence of systemic folate deficiency, the discovery of autoantibodies (AuAbs) to folate receptor α (FRα) that block the uptake of folate offers one mechanism to explain the response to folate in these disorders. The association of FRα AuAbs with pregnancy-related complications, CFD syndrome, and autism spectrum disorders and response to folate therapy is highly suggestive of the involvement of these AuAbs in the disruption of brain development and function via folate pathways. The two types of antibodies identified in the serum of patients are blocking antibody and binding antibody. The two antibodies can be measured by the specific assays described and exert their pathological effects either by functional blocking of folate transport as previously shown or hypothetically by disrupting the FR by an antigen-antibody-mediated inflammatory response. We have identified both IgG and IgM AuAbs in these conditions. The predominant antibodies in women with NTD pregnancy belong to the IgG1 and IgG2 isotype and in CFD children, the IgG1 and IgG4 isotype. This review describes the methods used to measure these AuAbs, their binding characteristics, affinity, cross-reactivity, and potential mechanisms by which folate therapy could work. Because these AuAbs are associated with various pathologies during fetal and neonatal development, early detection and intervention could prevent or reverse the consequences of exposure to these AuAbs.
Subject(s)
Autoantibodies/blood , Child Development Disorders, Pervasive/diagnosis , Folate Receptor 1/immunology , Folic Acid Deficiency/diagnosis , Neural Tube Defects/diagnosis , Antibodies, Blocking/blood , Antibodies, Blocking/drug effects , Antibody Affinity/drug effects , Autoantibodies/immunology , Child , Child Development Disorders, Pervasive/blood , Child Development Disorders, Pervasive/immunology , Female , Folic Acid/analogs & derivatives , Folic Acid/pharmacology , Folic Acid Deficiency/blood , Folic Acid Deficiency/immunology , Humans , Immunoglobulin G/blood , Immunoglobulin Isotypes/blood , Neural Tube Defects/blood , Neural Tube Defects/immunology , PregnancyABSTRACT
One of the established animal models for autoimmune disease antiphospholipid syndrome (APS) is TTd hyperimmunization of mice. Tetanus toxoid (TTd) and plasma protein ß2GPI share structural homology so that immunization with TTd induces appearance of cross-reactive antibodies. In this paper, we have investigated the presence and dynamic of fluctuation of specific (anti-TTd) and auto (anti-ß2GPI) antibodies induced in BALB/c mice during secondary immune response after TTd immunization with alhydrogel or glycerol as adjuvants. In addition, we followed the induced reproductive pathology as a sign of autoimmune outcome. We show undoubtedly adjuvant dependance of (1) level of induced anti-TTd IgG antibodies, (2) changes in levels of low-affinity anti-ß2GPI IgG antibodies, and (3) change in fecundity and fertility during secondary immune response. These findings once more indicate the importance of chosen adjuvants used for successful immunization and eventual autoantibody outcome, this time associated with the processes involving low affinity, natural antibodies.